title: Radioimmunotherapy for lymphoma - analysis of clinical trials and treatment algorithms.
abstract: Ibritumomab, an (90)Yttrium ((90)Y) labelled radioimmunoconjugate, is registered in Europe to treat follicular lymphomas. Its mode of action combines the selectivity of monoclonal antibodies with the efficiency of radiotherapy, making it a unique and useful therapeutic agent. This paper is for haemato-oncologists with a decent practice in lymphoma therapy, who have not yet used ibritumomab themselves. It summarizes clinical trials with radioimmunotherapy, indicating clinical situations where it may be specifically useful.
authors.affiliation: Department of Haematology, Collegium Medicum, Jagiellonian University, Kraków, Poland. wj2004@wp.pl
authors.forename: Wojciech
authors.initials: W
authors.lastname: Jurczak
authors.forename: Alicja
authors.initials: A
authors.lastname: Hubalewska-Dydejczyk
authors.forename: Agnieszka
authors.initials: A
authors.lastname: Giza
authors.forename: Anna
authors.initials: A
authors.lastname: Sowa-Staszczak
authors.forename: Bohdan
authors.initials: B
authors.lastname: Huszno
authors.forename: Aleksander B
authors.initials: AB
authors.lastname: Skotnicki
mesh_terms: D000465:Algorithms; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D002986:Clinical Trials as Topic / Q000639:trends*; D020000:Decision Support Systems, Clinical; D005060:Europe; D006801:Humans; D008223:Lymphoma / Q000532:radiotherapy*; D016499:Radioimmunotherapy / Q000639:trends*; D019275:Radiopharmaceuticals / Q000627:therapeutic use
chemical_list: D000911:Antibodies, Monoclonal; D019275:Radiopharmaceuticals; C422802:ibritumomab tiuxetan